The last patient started treatment in December 2020; clinical database lock occurred in October 2022.
The primary endpoint of overall response rate (ORR) per RECIST v1.1 assessed by blinded independent central review (BICR) was not met.
Inasmuch as ONCS had a restructuring and 45% layoff in Oct 2022 (#msg-170117130)—just as the database for this trial was locked—you would think investors would’ve taken that as a “tell.”
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.